Home›Trial›NCT05170425
NCT05170425ACTIVE NOT RECRUITING

LAMBDA 002 (Lung Registry) Study

Study Summary

The LAMBDA 002 registry study is an observational, longitudinal, multi-center study observing patients undergoing lung transplant.

Conditions
Lung Transplant Rejection
Interventions / Drugs
Prospera
View on ClinicalTrials.gov ↗
Sponsor
NTRA
Natera Inc
Genetics Diagnostics
D48/100
Study Details
Enrollment154 participants
Primary Completion—
Lead SponsorNatera, Inc.
Data Retrieved2026-04-11 04:23:02.260821+00:00
What This Trial Means for Biotech Investors
Trial Phase Context
Status & Expected Data

Enrollment is complete. The trial is in its follow-up or data collection phase — a readout may occur on or near the primary completion date.

Enrolled: 154 participants
Sponsor Catalyst Profile

Natera Inc (NTRA) is the sponsoring company for this trial. BiotechSign currently grades this company D (48/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

NTRA Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.